DKK4 and neoplasm: Emerging evidence has shown that imatinib combined with immunotherapy produces a more significant effect on tumor suppression, because of the simultaneous effects that imatinib directly inhibits tumor cells and potentiates antitumor T cells response.31, 32, 33 DKK4, forming the immune‐suppressive microenvironment, is supposed to account for the weak sensitivity to imatinib to some extent, and is a potential therapeutic target to contribute to the combined therapy.